AstraZeneca Nabs CinCor’s Hypertension Asset In $1.3bn Acquisition
Potential Combination With Farxiga
The UK major is acquiring CinCor in a deal that could be worth up to $1.8bn, in return getting hold of its Phase II hypertension candidate, baxdrostat, which offers combination potential with Farxiga.
